Last reviewed · How we verify
SGLT2 inhibitor
SGLT2 inhibitor is a SGLT2 inhibitor Small molecule drug developed by University of Minnesota. It is currently FDA-approved for Type 2 diabetes mellitus, Heart failure with reduced ejection fraction, Chronic kidney disease. Also known as: Dapagliflozin, Empagliflozin, Canagliflozin, Canagliflozin, Invokana, empagliflozin, Dapagliflozin.
SGLT2 inhibitors block sodium-glucose cotransporter 2 in the kidney, preventing glucose reabsorption and promoting urinary glucose excretion.
SGLT2 inhibitors are a class of medications that work by inhibiting sodium/glucose cotransporter 2 (SGLT2) in the kidney, which leads to the inhibition of glucose reabsorption and a subsequent lowering of blood sugar. They are being studied in various clinical trials, including the ACHIEVE-SGLT2i registry, for conditions such as adult congenital heart disease.
At a glance
| Generic name | SGLT2 inhibitor |
|---|---|
| Also known as | Dapagliflozin, Empagliflozin, Canagliflozin, Canagliflozin, Invokana, empagliflozin, Dapagliflozin, ertugliflozin |
| Sponsor | University of Minnesota |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 (sodium-glucose cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Diabetes, Cardiovascular, Nephrology |
| Phase | FDA-approved |
Mechanism of action
SGLT2 is a transporter protein in the proximal tubule of the nephron that normally reabsorbs filtered glucose back into the bloodstream. By inhibiting this transporter, SGLT2 inhibitors increase urinary glucose loss, thereby lowering blood glucose levels independently of insulin secretion. This mechanism also produces osmotic diuresis and has cardioprotective and renoprotective effects beyond glucose control.
Approved indications
- Type 2 diabetes mellitus
- Heart failure with reduced ejection fraction
- Chronic kidney disease
- Type 1 diabetes (in combination with insulin)
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Polyuria
- Diabetic ketoacidosis
- Acute kidney injury
- Hypotension
Key clinical trials
- Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory Dysfunction (PHASE3)
- Sodium-Glucose Cotransporter 2 Inhibitor Use in a National Heart Failure Telemonitoring Program
- Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients. (NA)
- Surgical or Medical Treatment (PHASE4)
- Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease (PHASE3)
- Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors
- The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure (PHASE4)
- SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SGLT2 inhibitor CI brief — competitive landscape report
- SGLT2 inhibitor updates RSS · CI watch RSS
- University of Minnesota portfolio CI
Frequently asked questions about SGLT2 inhibitor
What is SGLT2 inhibitor?
How does SGLT2 inhibitor work?
What is SGLT2 inhibitor used for?
Who makes SGLT2 inhibitor?
Is SGLT2 inhibitor also known as anything else?
What drug class is SGLT2 inhibitor in?
What development phase is SGLT2 inhibitor in?
What are the side effects of SGLT2 inhibitor?
What does SGLT2 inhibitor target?
Related
- Drug class: All SGLT2 inhibitor drugs
- Target: All drugs targeting SGLT2 (sodium-glucose cotransporter 2)
- Manufacturer: University of Minnesota — full pipeline
- Therapeutic area: All drugs in Diabetes, Cardiovascular, Nephrology
- Indication: Drugs for Type 2 diabetes mellitus
- Indication: Drugs for Heart failure with reduced ejection fraction
- Indication: Drugs for Chronic kidney disease
- Also known as: Dapagliflozin, Empagliflozin, Canagliflozin, Canagliflozin, Invokana, empagliflozin, Dapagliflozin, ertugliflozin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing